Ligand Pharmaceuticals. has been granted a patent for high-throughput screening methods that utilize microcapillary arrays to assess the association of variant proteins with target molecules. The process involves measuring signals from reporter elements to identify and isolate proteins of interest from large populations. GlobalData’s report on Ligand Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Ligand Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Ligand Pharmaceuticals's grant share as of June 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
High-throughput screening of variant proteins using microcapillary arrays
The granted patent US12024705B2 outlines a method and system for selecting proteins from a population of variant proteins using a microcapillary array. The method involves providing a microcapillary array where each microcapillary contains a cellular expression system that expresses a variant protein, an immobilized target molecule, and a reporter element. The variant protein interacts with the target molecule, and the association is measured through signals from the reporter element. This process allows for the identification of microcapillaries of interest, from which the contents can be isolated using an extraction device. The patent specifies that the cellular expression system can be derived from various organisms, including animals, fungi, bacteria, insects, or plants, and that the variant proteins may include antibodies or specific proteins from mice, chickens, or rabbits.
Additionally, the patent details various configurations for the immobilized target molecule, which can be placed on surfaces within the microcapillaries. The extraction device may utilize a laser to isolate the contents, targeting the water-glass interface within the microcapillary. The claims also highlight that each microcapillary can contain a single variant protein or a combination of up to five different proteins. Furthermore, the system allows for the propagation of cell or virus clones from the isolated contents and includes the identification and characterization of the variant proteins. The reporter element is often a fluorescently-labeled antibody, enhancing the detection of protein interactions. Overall, this patent presents a sophisticated approach to protein selection that could have significant implications in biotechnological and pharmaceutical applications.
To know more about GlobalData’s detailed insights on Ligand Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
